Results 151 to 160 of about 3,103 (173)

Long-acting cabotegravir PrEP: a time for cautious optimism

The Lancet HIV, 2023
David Wj, Griffin, Jennifer F, Hoy, James H, McMahon   +2 more
openaire   +2 more sources

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

Lancet, The, 2017
Joseph J Eron, Daniel Podzamczer, Jonathan B Angel   +2 more
exaly  

Cabotegravir/rilpivirine

Reactions Weekly, 2019
openaire   +1 more source

Chasing the cabotegravir tail: implications for prevention

The Lancet HIV, 2020
openaire   +2 more sources

Early virological failure with cabotegravir/rilpivirine

Journal of Antimicrobial Chemotherapy
L Bailón, S Sábato, J Coll, J R Santos, C Miranda, T Puig, A D´Avolio, R Paredes, J Moltó, E Negredo   +9 more
openaire   +4 more sources

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

Lancet Infectious Diseases, The, 2015
Joseph J Eron
exaly  

Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus–uninfected Individuals in HPTN 077

Clinical Infectious Diseases, 2020
Raphael J Landovitz, Sahar Zangeneh, Beatriz Gilda J Grinsztejn   +2 more
exaly  

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

Biomaterials, 2018
Tian Zhou, Hang Su, Prasanta K Dash
exaly  

Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial

HIV Clinical Trials, 2018
Ian Frank, Kenneth Mayer, David T Dunn
exaly  

Cabotegravir. HIV integrase inhibitor, anti-HIV agent

Drugs of the Future, 2015
null Han, Y., null Mesplede, T., null Wainberg, M.A.   +2 more
openaire   +1 more source